Smith & Nephew vs Baxter International: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Smith & Nephew PLC (SN.LSE)

Q3 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

August 202623 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Latest23 Jul – 6 Oct 2026

▲3▼1

New product launches and FDA win offset cut to sales growth outlook

Full-year sales growth guidance cut to ~4% First-half profit rose to $380 million and revenue grew to $3.10 billion, but management cut the full-year revenue growth forecast to about 4% from about 6%, citing soft US Orthopaedics and Advanced Wound Bioactives. A slower sales outlook lowers future earnings expectations and weighs on the shares.
The guidance cut is the main negative force on the stock this period.
FDA clears first-of-its-kind TESSA surgical navigation system Smith+Nephew won FDA De Novo clearance for its TESSA Spatial Surgery System, a new-category device that overlays patient-specific 3D models onto live surgical video. It launches commercially in Q3 2026 and could open a new, higher-priced technology franchise in knee surgery.
A regulatory first that adds a new growth product line.
Expanded outpatient surgery platform targets fast-growing market The company broadened its ASC Solutions strategy and ASC ONE delivery model, combining its devices, data and partners to serve ambulatory surgery centres. The outpatient market is projected to grow from $160.7 billion in 2026 to $205.5 billion by 2030, giving Smith+Nephew a larger channel for its procedural technologies.
Shows a structural demand driver beyond one quarter.
New trauma and cartilage products broaden the portfolio Smith+Nephew launched the EVOS PELVIC Plating System in the US for pelvic and acetabular fractures, and made its CARTIHEAL AGILI-C cartilage implant commercially available in Europe after positive five-year trial data. Both add new revenue streams in higher-value orthopaedic procedures.
Product launches are the main positive pipeline news this period.

Baxter International Inc (BAX)

Q3 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

August 202629 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.

Latest29 Jul – 7 Sep 2026

▲2▼2

Baxter's Q2 beat and raised 2026 outlook lift shares, but margins stay squeezed

Q2 beat and raised guidance Baxter's second-quarter sales rose 5% to $2.96 billion and adjusted profit hit 56 cents a share, far above the 37 cents analysts expected. Management raised full-year sales and earnings guidance, a sign the core business is steadier than feared. The stock jumped sharply on the news.
This is the main new event that moved BAX and reset expectations for the year.
Debt buyback upsized Baxter increased its cash tender offer cap to $600 million, buying back several older bonds. Paying down or refinancing debt can lower interest costs and steady the balance sheet, which supports the stock by reducing financial risk.
It is a new capital-structure action that affects how investors view BAX's debt load.
Margins still under pressure Even with the upbeat quarter, adjusted gross margin fell to 38.6% and operating margin slipped to 14.2%, hurt by costly inventory, manufacturing expenses and tariffs. That means profit per sale is still shrinking, a real counterweight to the good headline numbers.
It is the main negative in the new results and explains why the beat is not purely good news.
Infusion pump hold drags on Baxter's Novum IQ large-volume pump remains under a shipment and installation hold, with customer returns and a shift to older Spectrum pumps. That is holding back Infusion Systems sales and is an execution risk that could keep a lid on growth until resolved.
It is a specific new operational risk flagged alongside the raised outlook.